Your session is about to expire
Harvoni vs Epclusa
Introduction
For patients diagnosed with chronic hepatitis c virus (HCV) infections, certain antiviral medications can help in managing symptoms and reducing the viral load. Harvoni and Epclusa are two such drugs that are often prescribed for HCV treatment. Both meds operate by inhibiting proteins necessary for HCV replication but affect different genotypes of the virus. Harvoni is a combination of ledipasvir and sofosbuvir, typically recommended for genotype 1 infection - the most common type in the United States. On the other hand, Epclusa consists of sofosbuvir and velpatasvir, making it effective against all six major genotypes of HCV hence offering a broader spectrum efficacy compared to Harvoni.
What is Harvoni?
Harvoni and Epclusa are both ground-breaking medications that have revolutionized the treatment of hepatitis c, a disease caused by an infection with the Hepatitis C Virus (HCV). Both drugs were developed and marketed by Gilead Sciences. Harvoni, which was approved by the FDA in 2014, is a combination therapy that contains two antiviral medicines: ledipasvir and sofosbuvir. It works by preventing HCV from multiplying in your body.
On the other hand, Epclusa is another combination medication containing sofosbuvir and velpatasvir. This drug received its approval from FDA in 2016. Unlike Harvoni which treats specific genotypes of HCV (genotype 1), Epclusa can be used to treat all six major forms or genotypes of HCV; this broad-spectrum activity has been considered one of its primary advantages over Harvoni.
Both these drugs have transformed how we approach HCV treatment due to their high cure rates and lower side effect profiles compared with older therapies. However, they work somewhat differently on different strains or 'genotypes' of the virus.
What conditions is Harvoni approved to treat?
Harvoni and Epclusa are both approved for the treatment of different types of chronic hepatitis c virus (HCV):
- Harvoni is used to treat genotypes 1, 4, 5, and 6 HCV.
- Epclusa can be used to treat all six major forms of HCV (genotypes 1-6), making it a broader spectrum antiviral.
Both drugs can be used with or without ribavirin, another medication used in the treatment of HCV.
How does Harvoni help with these illnesses?
Harvoni helps to manage Hepatitis c by blocking the virus's ability to replicate in the body. It does this through a combination of two direct-acting antiviral drugs: ledipasvir, which targets and inhibits a specific protein necessary for the virus to reproduce; and sofosbuvir, which interferes with the RNA replication of the hepatitis C virus. The hepatitis C virus is an infectious disease that primarily affects liver function, causing inflammation and potentially leading to severe liver damage over time. Individuals with Hepatitis C have high levels of this viral load. Therefore, by reducing its ability to replicate, Harvoni can limit further liver damage from Hepatitis C and help patients manage their condition more effectively.
On the other hand, Epclusa also works against Hepatitis C but it has broader genotype coverage compared to Harvoni making it effective against all genotypes (1-6) of HCV infection. It combines two active substances - sofosbuvir like in Harvoni treatment regimen along with velpatasvir targeting different proteins essential for viral reproduction.
What is Epclusa?
Epclusa is a brand name for a combination of sofosbuvir and velpatasvir, which are antiviral medications that prevent hepatitis c virus (HCV) from multiplying in your body. It acts as an inhibitor of the viral NS5A protein and can be effective against all genotypes of the HCV. Epclusa was first approved by the FDA in 2016. As Epclusa targets multiple steps in the HCV lifecycle, it has been shown to maintain high sustained virologic response rates across all HCV genotypes, including those with compensated cirrhosis or without cirrhosis.
Its broad-spectrum action means that its efficacy profile is different than single-target drugs like Harvoni (ledipasvir/sofosbuvir), particularly due to its ability to treat all types of HCV infections. Common side effects include headache and tiredness but severe side effects such as reactivation of Hepatitis b infection have been reported on rare occasions. The effects on various stages of virus multiplication can make it beneficial for treating chronic Hepatitis C patients who do not respond well or cannot be treated with other direct-acting antiviral regimens such as Harvoni.
What conditions is Epclusa approved to treat?
Epclusa has been approved by the FDA for treating a wide range of conditions including:
- Chronic hepatitis c virus (HCV) infection in adults, covering all genotypes from 1 to 6.
- In combination with ribavirin, it can also be used for those with decompensated cirrhosis.
How does Epclusa help with these illnesses?
Epclusa is a potent antiviral medication that works by targeting and disrupting the life cycle of Hepatitis c virus, thereby preventing it from multiplying in your body. It contains two active ingredients: sofosbuvir and velpatasvir. Sofosbuvir impedes the replication process of the hepatitis C viral RNA while velpatasvir targets a protein vital to the completion of this cycle. This dual action makes Epclusa effective against all genotypes of Hepatitis C, which gives it an edge over Harvoni that is primarily used for treating genotype 1. It's often prescribed when patients have varying or indeterminate types of Hepatitis C, or if they haven't responded as expected to other forms like Harvoni.
How effective are both Harvoni and Epclusa?
Both ledipasvir/sofosbuvir (Harvoni) and sofosbuvir/velpatasvir (Epclusa) are potent antiviral drugs used in the treatment of chronic hepatitis c, with high rates of sustained virologic response. Harvoni was approved by the FDA in 2014, only two years before Epclusa's approval in 2016. The effectiveness of Harvoni and Epclusa has been directly compared in several clinical trials, demonstrating similar efficacy profiles across multiple genotypes of the virus.
A review on ledipasvir/sofosbuvir published in 2015 showed that it is effective against genotype 1 hepatitis C infection from as early as the first week of treatment and its side effect profile is generally well-tolerated. As one of the first direct-acting antiviral drug combinations to be developed for hepatitis C treatment, there is a rich history and study into its effectiveness against this disease. In fact, optimal dosage found to be most efficacious was a combination pill containing 90 mg ledipasvir and 400 mg sofosbuvir taken once daily.
On the other hand, a meta-analysis conducted on sofosbuvir/velpatasvir demonstrated that it appears more broadly active than placebo or previous standard treatments across all six major HCV genotypes. While often considered after or alongside other direct-acting antiviral treatments due to its broad-spectrum activity against multiple HCV genotypes. Despite being newer than Harvoni, significant research supports using Epclusa either alone or co-prescribed with another medication such as ribavirin based on individual patient needs.
At what dose is Harvoni typically prescribed?
Both Harvoni and Epclusa are oral medications used for the treatment of chronic Hepatitis c. The standard dosage for adults using Harvoni is one tablet per day, containing 90 mg of ledipasvir and 400 mg of sofosbuvir. Treatment duration typically lasts 12 weeks, but can be extended to 24 weeks based on the severity of the disease or previous treatments. Similarly, Epclusa also requires a daily intake of one tablet which consists of 100mg velpatasvir and 400mg sofosbuvir for a period usually spanning over a course of 12 weeks. Dosage adjustments may be required in patients with severe renal impairment or end-stage renal disease, hence it's crucial to always follow your healthcare provider's instructions regarding dose administration.
Related trials for harvoni and epclusa
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Epclusa typically prescribed?
Epclusa treatment is typically initiated with a fixed dose of 1 tablet (400 mg sofosbuvir and 100 mg velpatasvir) taken orally once daily. This regimen persists for a consistent duration of 12 weeks, regardless of the patient's disease history or liver function status. There are no incremental increases in dosage as seen with other medications; instead, Epclusa maintains its efficacy by providing a steady, reliable level of medication throughout the course. The simplicity and effectiveness of this one-pill-a-day dosage makes it easier for patients to adhere to their treatment plan without fear of adjustments over time.
What are the most common side effects for Harvoni?
Common side effects shared by both Harvoni and Epclusa can include:
- Fatigue (general weakness and tiredness)
- Headache
- Nausea, vomiting, or diarrhea
- Insomnia (difficulty sleeping)
- Weakness or lack of energy
- Rash
- Irritability and mood changes
- Muscle pains
Should you experience any of these symptoms to a severe degree, it's important to contact your healthcare provider promptly. Please note that while these medications are similar in purpose - treating hepatitis c - their side effect profiles may slightly vary due to the different active ingredients involved. Always consult with your healthcare professional prior to starting any new medication regimen.
Are there any potential serious side effects for Harvoni?
While Harvoni and Epclusa are generally well-tolerated, they can cause side effects in some individuals. These may include:
- Allergic reactions: Signs of a severe allergic reaction such as swelling of the face or throat, difficulty breathing, hives, rash with blistering or peeling skin.
- Vision changes: Blurred vision or other visual disturbances could occur. If you notice these symptoms while taking either medication, contact your doctor immediately.
- Heart palpitations: Some patients taking these medications have reported an irregular heart rhythm or fast pounding heartbeat. Seek emergency medical attention if you experience chest pain, shortness of breath or feel like you might pass out.
- Neurological issues: In rare cases, severe neurological symptoms have been reported including extreme muscle stiffness, confusion and tremors.
- Low sodium levels (hyponatremia): This condition can lead to headache, slurred speech and loss of coordination among others.
If any signs similar to serotonin syndrome appear such as hallucinations, fever sweating shivering fast heart rate , twitching nausea vomiting diarrhea it's advised to seek immediate medical help.
Remember that everyone's body reacts differently to medication - what works well for one person may not work as effectively for another. Always consult with your healthcare provider when deciding on treatment options.
What are the most common side effects for Epclusa?
Epclusa, like Harvoni, is an antiviral medication used to treat chronic Hepatitis c. However, it may cause different side effects including:
- Fatigue
- Nausea and headache
- Insomnia or sleep problems
- Diarrhea
- Mild rash or itchiness
- Anemia (low levels of red blood cells)
- Weakness or lack of energy While these symptoms are generally mild and manageable, severe side effects such as slowed heart rate can also occur in rare cases. Always consult your doctor if you experience any discomfort while taking Epclusa.
Are there any potential serious side effects for Epclusa?
While Epclusa is a highly effective medication for the treatment of Hepatitis c, it's important to be aware of potential serious side effects. These can include:
- Signs of allergic reaction or severe skin reaction: hives, itching, fever, swollen glands, difficulty breathing, swelling in your face or throat.
- Symptoms indicating potential liver problems such as fatigue and weakness; loss of appetite; upper belly pain; dark urine; yellowing eyes or skin (jaundice).
- Depression indicators: feeling sad or empty; irritability; trouble concentrating; sleep disturbances like insomnia.
- Rapid heart rate and/or chest discomfort.
- Changes in vision that could indicate new or worsening eye problems.
If you experience any unusual symptoms while taking Epclusa, promptly contact your healthcare provider. It's crucial to report these signs early so they can be addressed properly by medical professionals.
Contraindications for Harvoni and Epclusa?
Both Harvoni and Epclusa, like many other antiviral medications, can cause side effects in some patients. If you notice an increase in symptoms or new symptoms such as fatigue, headache, nausea, insomnia or any unusual signs after taking these drugs for Hepatitis c treatment, please seek immediate medical attention.
Neither Harvoni nor Epclusa should be taken if you are already using certain drugs that affect liver enzymes (specifically those that inhibit P-glycoprotein), because this can interfere with the effectiveness of your Hepatitis C treatment. Always tell your physician which medications you are currently taking; certain interacting drugs may need to be discontinued well before starting treatment with Harvoni or Epclusa to prevent harmful interactions.
How much do Harvoni and Epclusa cost?
For the brand-name versions of these drugs:
- The price of a 28-day supply of Harvoni (90 mg/400 mg) averages around $31,500, which works out to approximately $1125 per day.
- The price of a 28-day supply of Epclusa (100 mg/400 mg) is also substantial, averaging about $26,400. This amounts to roughly $943 per day.
Thus, if you are on an equal dosage basis for each drug (i.e., one tablet per day), then brand-name Epclusa is less expensive on a daily treatment basis compared to Harvoni. However, it's critical to note that cost should not be the primary consideration in determining which hepatitis c drug is best suited for you.
Unfortunately, there aren't generic versions available yet for either Harvoni or Epclusa due to patent protections and other factors related to pharmaceutical regulations. As such costs remain quite high; however financial assistance programs may help offset some expenses. Always consult with your healthcare provider before making any decisions regarding medication choices.
Popularity of Harvoni and Epclusa
Harvoni and Epclusa are two of the most commonly prescribed direct-acting antiviral (DAA) regimens for chronic Hepatitis c.
Harvoni was estimated to have been prescribed to approximately 70,000 patients in the US in 2020. Harvoni is a combination of ledipasvir and sofosbuvir, targeted specifically at the treatment of genotype 1 hepatitis C virus (HCV), which accounts for about 75% of HCV cases in the United States.
Epclusa, on the other hand, is a broad-spectrum DAA that contains sofosbuvir and velpatasvir. It can be used to treat all genotypes of HCV. In terms of prescriptions filled, Epclusa has seen an upward trend since its approval by FDA in June 2016 due to its broader use application across different genotypes.
Both Harvoni and Epclusa offer high cure rates with relatively few side effects compared to older treatments for Hepatitis C. However, their cost may limit accessibility for some patients.
Conclusion
Both Harvoni and Epclusa have revolutionized the treatment of Hepatitis c, converting a previously chronic disease into one that is curable in most cases. Both drugs are backed by numerous clinical studies demonstrating their efficacy over older treatments or placebo.
Harvoni contains two active ingredients - ledipasvir and sofosbuvir, while Epclusa combines sofosbuvir with velpatasvir. The choice between these two medications usually depends on the strain (genotype) of Hepatitis C virus present within a patient's body. Harvoni is typically prescribed for genotypes 1, 4, 5 and 6 while Epclusa covers all six main genotypes.
Both drugs are available as generics which can lead to substantial cost savings especially when patients must pay out of pocket. Treatment duration may range from eight to twelve weeks depending on several factors including whether cirrhosis is present.
The side effect profiles for both medications are similar; they're generally well-tolerated with common side effects being headache and fatigue. Regardless of the medication chosen, it’s critical for patients to take them exactly as directed until completion even if symptoms improve before finishing the course.